William V Padula1, Shiona Heru2, Jonathan D Campbell3. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA. wpadula@jhu.edu. 2. Commonwealth of Massachusetts Group Insurance Commission (GIC), Boston, MA, USA. 3. Center for Pharmaceutical Outcomes Research (CePOR), Department of Clinical Pharmacy, University of Colorado, Aurora, CO, USA.
Abstract
BACKGROUND: Recently, the Massachusetts Group Insurance Commission (GIC) prioritized research on the implications of a clause expressly prohibiting the denial of health insurance coverage for transgender-related services. These medically necessary services include primary and preventive care as well as transitional therapy. OBJECTIVE: To analyze the cost-effectiveness of insurance coverage for medically necessary transgender-related services. DESIGN: Markov model with 5- and 10-year time horizons from a U.S. societal perspective, discounted at 3% (USD 2013). Data on outcomes were abstracted from the 2011 National Transgender Discrimination Survey (NTDS). PATIENTS: U.S. transgender population starting before transitional therapy. INTERVENTIONS: No health benefits compared to health insurance coverage for medically necessary services. This coverage can lead to hormone replacement therapy, sex reassignment surgery, or both. MAIN MEASURES: Cost per quality-adjusted life year (QALY) for successful transition or negative outcomes (e.g. HIV, depression, suicidality, drug abuse, mortality) dependent on insurance coverage or no health benefit at a willingness-to-pay threshold of $100,000/QALY. Budget impact interpreted as the U.S. per-member-per-month cost. KEY RESULTS: Compared to no health benefits for transgender patients ($23,619; 6.49 QALYs), insurance coverage for medically necessary services came at a greater cost and effectiveness ($31,816; 7.37 QALYs), with an incremental cost-effectiveness ratio (ICER) of $9314/QALY. The budget impact of this coverage is approximately $0.016 per member per month. Although the cost for transitions is $10,000-22,000 and the cost of provider coverage is $2175/year, these additional expenses hold good value for reducing the risk of negative endpoints--HIV, depression, suicidality, and drug abuse. Results were robust to uncertainty. The probabilistic sensitivity analysis showed that provider coverage was cost-effective in 85% of simulations. CONCLUSIONS: Health insurance coverage for the U.S. transgender population is affordable and cost-effective, and has a low budget impact on U.S. society. Organizations such as the GIC should consider these results when examining policies regarding coverage exclusions.
BACKGROUND: Recently, the Massachusetts Group Insurance Commission (GIC) prioritized research on the implications of a clause expressly prohibiting the denial of health insurance coverage for transgender-related services. These medically necessary services include primary and preventive care as well as transitional therapy. OBJECTIVE: To analyze the cost-effectiveness of insurance coverage for medically necessary transgender-related services. DESIGN: Markov model with 5- and 10-year time horizons from a U.S. societal perspective, discounted at 3% (USD 2013). Data on outcomes were abstracted from the 2011 National Transgender Discrimination Survey (NTDS). PATIENTS: U.S. transgender population starting before transitional therapy. INTERVENTIONS: No health benefits compared to health insurance coverage for medically necessary services. This coverage can lead to hormone replacement therapy, sex reassignment surgery, or both. MAIN MEASURES: Cost per quality-adjusted life year (QALY) for successful transition or negative outcomes (e.g. HIV, depression, suicidality, drug abuse, mortality) dependent on insurance coverage or no health benefit at a willingness-to-pay threshold of $100,000/QALY. Budget impact interpreted as the U.S. per-member-per-month cost. KEY RESULTS: Compared to no health benefits for transgender patients ($23,619; 6.49 QALYs), insurance coverage for medically necessary services came at a greater cost and effectiveness ($31,816; 7.37 QALYs), with an incremental cost-effectiveness ratio (ICER) of $9314/QALY. The budget impact of this coverage is approximately $0.016 per member per month. Although the cost for transitions is $10,000-22,000 and the cost of provider coverage is $2175/year, these additional expenses hold good value for reducing the risk of negative endpoints--HIV, depression, suicidality, and drug abuse. Results were robust to uncertainty. The probabilistic sensitivity analysis showed that provider coverage was cost-effective in 85% of simulations. CONCLUSIONS: Health insurance coverage for the U.S. transgender population is affordable and cost-effective, and has a low budget impact on U.S. society. Organizations such as the GIC should consider these results when examining policies regarding coverage exclusions.
Entities:
Keywords:
budget impact analysis; cost-effectiveness analysis; health insurance coverage; health law; preventive care; transgender health
Authors: D Bishai; J Sindelar; E P Ricketts; S Huettner; L Cornelius; J J Lloyd; J R Havens; C A Latkin; S A Strathdee Journal: J Health Econ Date: 2007-12-05 Impact factor: 3.883
Authors: Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau Journal: Value Health Date: 2013-12-13 Impact factor: 5.725
Authors: Shane D Morrison; Geolani W Dy; H Jonathan Chong; Sarah K Holt; Nicholas B Vedder; Mathew D Sorensen; Byron D Joyner; Jeffrey B Friedrich Journal: J Grad Med Educ Date: 2017-04
Authors: Max Lichtenstein; Laura Stein; Erin Connolly; Zil G Goldstein; Tyler Martinson; Linda Tiersten; Sangyoon J Shin; John Henry Pang; Joshua D Safer Journal: Transgend Health Date: 2020-09-02
Authors: Daphna Stroumsa; Halley P Crissman; Vanessa K Dalton; Giselle Kolenic; Caroline R Richardson Journal: Ann Fam Med Date: 2020-11 Impact factor: 5.166
Authors: Joseph K Canner; Omar Harfouch; Lisa M Kodadek; Danielle Pelaez; Devin Coon; Anaeze C Offodile; Adil H Haider; Brandyn D Lau Journal: JAMA Surg Date: 2018-07-01 Impact factor: 14.766
Authors: Robin Christian; Amy Anderson Mellies; Alison Grace Bui; Rita Lee; Leo Kattari; Courtney Gray Journal: J Gen Intern Med Date: 2018-05-15 Impact factor: 5.128